Objectives. To identify the pathogenetic mechanisms of central nervous system (CNS) syndromes of systemic lupus erythematosus (SLE) as described in the literature.
The origin of the central nervous system (CNS) manifestations of systemic lupus erythematosus (SLE) used to be largely a mystery, but there has been some progress in our understanding. Inflammatory disorders are no longer considered to be the main cause of cerebral damage. It is now generally acknowledged that most changes in the cerebral vasculature are due to complex processes that are in part immunological and in part due to other factors. This insight has led to diversification of therapy, probably to the benefit of patients. It is less clear to what extent an immunological attack on the white matter or on neuronal cell bodies or synapses plays a role in the disease mechanisms and whether there is overlap with multiple sclerosis (MS). No one doubts that some of the mechanisms involved in so-called neuropsychiatric SLE are psychological. However, the border between the biological and psychological dimensions in the CNS manifestations is not always clear.
In a companion paper, based on a literature investigation, we established that SLE may induce 16 clinical CNS syndromes w1x. The purpose of the present investigation is to identify the pathogenetic mechanisms of these syndromes, as described in the literature, and to evaluate their significance.
Methods

Patients
The investigation concerned the mechanisms of SLEinduced CNS syndromes in children and adults of either sex w1x. Neonatal lupus was not included.
Definition of SLE-induced CNS syndromes SLE was considered to be present if a patient had any four of the 11 criteria defined in 1982 by the American College of Rheumatology (ACR) or modified by the ACR in 1997 w2, 3x. A CNS syndrome was accepted as being inducible by SLE when it had been identified as such in a previous investigation w1x, and when a secondary origin had been ruled out or was considered unlikely. A syndrome was considered as of secondary origin when (i) it was a side-effect of drugs used for SLE treatment, (ii) it was due to an immunocompromised status (e.g. intracranial infection), (iii) it was obviously due to hypofunction or dysfunction of other internal organs, or (iv) it was secondary to another CNS syndrome.
The search for literature A PUBMED search was performed for studies in English, French or German concerning mechanisms of CNS manifestations of SLE published from 1980 onwards. Original articles, letters and reviews were accepted. We first asked for articles covering the combinations 'SLE and CNS' and 'SLE and CNS diseases'. Subsequently, we asked for the combinations of SLE and specific mechanisms related to CNS syndromes. The total number of MeSH terms used was 42; these will be specified in the subheadings in the Results section. We studied abstracts of titles that seemed promising, and articles of interest were selected and analysed. The references in these articles were screened for other studies of interest. An article was of interest when it dealt with structural or functional changes in the CNS due to SLE, leading to neuropsychiatric symptoms; antibodies or other substances related to SLE causing symptoms; or psychological reactions to SLE responsible for neuropsychiatric symptoms. We also studied selected articles on related topics of other diseases, e.g. posterior reversible leucoencephalopathy, Devic's syndrome, magnetic resonance imaging (MRI) of spinal cord lesions due to MS, etc.
Eligibility of publications and data extraction
We considered original publications and reviews to be eligible when they dealt with possible pathogenetic mechanisms of one or several of the CNS syndromes of SLE. These studies were used as the basis for conclusions. Results of other studies will be mentioned to confirm conclusions. In general, we shall not refer to studies of mixed case series composed of patients with definite SLE and lupus-like disease, and when we deviate from this rule this will be indicated. A secondary origin of a CNS syndrome was considered not present or not likely when it had been excluded on sufficient grounds by the authors or when grounds for a secondary origin were not present or not demonstrable. The data extracted from publications depended on the type of study (cohort study, case report, etc.) and concerned clinical features of syndromes and findings at imaging or other laboratory investigations.
Criteria for inclusion of a mechanism or a category of mechanisms The four inclusion criteria are presented in the Box 1. For a mechanism or a category of mechanisms to be included, the presence of Criteria 1 and 4, 2 and 4, or 3 and 4 was required.
Results
Categories of pathogenetic mechanisms (MeSH terms: SLE plus CNS diseases; CNS)
The pathogenetic mechanisms that were traced in the literature were ordered into five categories, each comprising one or several different processes (Table 1) . We will evaluate the mechanism included in each of these categories, as far as deemed necessary, and provide reasons why they are likely or have been shown to be operative in SLE, or why they have to be excluded.
I. Ischaemia
The role of ischaemia in the causation of disorders of the CNS in patients with SLE is undisputed and is generally accepted as prominent. The changes caused by ischaemia may be in part irreversible and in part reversible, or they are entirely reversible. Reperfusion of an ischaemic area carries the risk of oedema and haemorrhage. Ischaemia is induced by a number of processes leading to transient or permanent narrowing or occlusion of vessels of different type and calibre. The factors mentioned in the literature as contributing to ischaemia in SLE are summarized in Table 2 (a) Cerebral infarcts in patients with SLE. 'Cerebral infarction' develops significantly more often in LACpositive than in LAC-negative patients, as shown in a long-term, prospective study of 37 positive patients vs 37 age-and sex-matched negative patients. 'Cerebral infarction' is a late phenomenon in this study w14x. In another prospective investigation, no relationship was established between 'cerebral vascular accidents' (not including transient ischaemic attacks) and the presence of ACL. The number of patients in this latter study was considerable (500) and the follow-up time was short (mean, 8 months) w15x.
(b) Thrombosis in patients with SLE. LAC and ACL are significantly related to arterial (myocardial and cerebral combined) and venous thrombosis in patients with SLE w4, 16x. In an investigation of 175 patients, LAC was the strongest risk factor both for arterial thrombosis wodds ratio (OR) 9.77, 95% confidence interval (CI) 1.74-31.15) w4x and venous thrombosis (OR 6.55, 95% CI 2.36-18.17) w4x. Screening of other APL components, e.g. anti-b 2 -glycoprotein I did not provide additional information w4, 16x. This conclusion is confirmed by results from a large data base, the Hopkins Lupus Cohort, which, however, also contains data from patients not complying with the ACR criteria for SLE w17, 18x.
(c) Thrombosis in non-SLE patients. Although the results of most investigations are consistent with an increased risk of incident cerebral ischaemia in patients with APL, there are also deviant findings wfor review, see reference 19x. Results from two large studies, one population-based, the other a cohort of male physicians, do not support the contention that immunoglobulin G (IgG) ACL is an independent risk factor for stroke w20, 21x. However, IgG ACL is significantly associated with future deep venous thrombosis w20x and myocardial infarction w22x. Results of other studies indicate that the titre rather than the presence of IgG ACL may be decisive for the association with thrombosis w23-26x.
Conclusions. There is an association of APL with arterial and venous thrombosis in patients with SLE wargument (b), abovex. LAC is a stronger risk factor than Ig ACL wargument (b)x. An association between APL and ischaemic stroke in patients with SLE is likely warguments (a) and (b)x. The presence of APL complies with Criteria 2 and 4 and is accepted as a mechanism contributing to cerebral ischaemia.
I.2: Other antibodies against anticoagulants in patients with SLE (MeSH terms: SLE plus the following: CNS diseases; blood coagulation disorders; protein C; protein S). Protein S levels tend to be decreased in patients with SLE. Antibodies to protein S were found in six of 27 SLE patients without APL. A relationship with cerebral artery thrombosis and ischaemic stroke was not established w27x.
Conclusions. The presence of antibodies to protein S does not (yet?) comply with the criteria for inclusion as a mechanism.
I.3: Premature atherosclerosis (MeSH terms: SLE plus the following: CNS diseases; arteriosclerosis; lipids). The risk factors for premature atherosclerosis in SLE are summarized in Table 3 wsee references 28-40x. The evidence that SLE is involved in premature atherosclerosis of extracranial or intracranial arteries can be summarized as follows.
(a) An investigation of 498 women with SLE revealed a high rate of coronary heart disease. In the 35-44 yr age category, the rate of myocardial infarction was 50 times that of women without SLE w31x. Vessel spasm I. 10 Other risk factors present in the general population (b) In 175 women with SLE, an independent and strong association was found of SLE with coronary events, with focal carotid plaques and increase in the intima-media wall thickness of the carotid artery w32x. Stroke was due to cerebral infarcts in 28 of 34 patients in three large retrospective case series comprising 591 patients with SLE w33-35x.
(c) Patients with SLE-even those in an inactive stage without renal disease who have not been treated with corticosteroids for the last 6 months-have a characteristic combination of high plasma levels of triglycerides and very low density lipoprotein and a low level of high-density lipoprotein w36, 39x.
(d) Chylomicron metabolism in 10 selected patients with inactive SLE, without renal disease, who were not treated with corticosteroids, was compared with that in healthy age-and sex-matched controls and was found to be abnormal because of insufficient lipolysis, putatively due to reduced lipoprotein lipase activity w36x.
Conclusions. There is good evidence of premature carotid artery atherosclerosis in SLE warguments (a) and (b)x. SLE induces a state of dyslipoproteinaemia and is thus likely to contribute to premature atherosclerosis warguments (c) and (d)x. Premature atherosclerosis complies with inclusion Criteria 1, 2 and 4 and is accepted as a mechanism.
I.4: Small-vessel angiopathy (MeSH terms: SLE plus the following: CNS diseases; CNS; pathology; brain; cognition disorders; MRI). (a) Authors of five studies describing post-mortem investigations of the brains of 88 patients agree that small-vessel angiopathy is the predominant structural abnormality w41-45x. Changes in the walls of affected vessels are described as proliferation of intimal cells, increase in fibrous tissue, and mucoid hyperplasia or hyalinization. The lumen of small vessels may become occluded by fibrin thrombi, organized thrombi or fibrous webs. Small vessels may be surrounded by microglia clusters, small infarcts, haemorrhages or 'white matter necrosis'. There are also perivascular inflammatory infiltrates w41, 44x. All of these changes may occur throughout the pia-arachnoid and the nervous tissue.
(b) On MRI, T 2 -weighted images of the brain reveal in many patients small punctate lesions of increased signal intensity, localized mainly in the periventricular and subcortical white matter. In two studies, these were seen in 21 of 40 patients with prior CNS manifestations and in 19 of 50 patients without CNS manifestations w46, 47; for review, see reference 48x. It is suggested that they represent small infarcts with loss of nerve fibres and local gliosis w49, 50x.
(c) The pathogenesis of these vascular changes is not clear w51x. Results of a meticulous histopathological investigation of four patients point to more prominent small-vessel angiopathy in patients with APL than in those without APL w45x.
(d) Cerebral small-vessel vasculopathy has been suggested to underlie the cognitive disorder of SLE patients who are otherwise without neuropsychiatric diseases w52x. In support of this hypothesis, cerebral small-vessel disease due to hypertension and ageing leads to predominantly subcortical dementia w53, 54x. In one patient with SLE, biopsy investigation pointed to small-vessel angiopathy as contributing to leucoencephalopathy w55x.
Conclusions. Cerebral small vessel angiopathy is the predominant histopathological abnormality in SLE wargument (a)x. It is suggested to cause cognitive disorder in many patients wargument (d)x. It complies with Criteria 1 and 4 and is accepted for inclusion as a mechanism.
I.5: Thrombosis (MeSH terms: SLE plus the following: intracranial thrombosis; cerebral artery diseases; thrombosis, carotid artery; sinus thrombosis intracranial; pseudotumour cerebri). (a) The incidence of ischaemic stroke in patients with SLE is increased w33, 34, 35; for review, see reference 1x and has been demonstrated in some cases to be due to occlusion of large arteries w10x. Premature atherosclerosis may be assumed to be involved in this occlusion and is in part due directly to SLE (see I.3: Premature atherosclerosis). Another process contributing to occlusion is the increased activation of the haemostatic system. Thromboxane biosynthesis is enhanced in patients with SLE, pointing to platelet activation, and the plasma level of a marker of thrombin generation (prothrombin fragments F1 + 2) is increased w6x. APL may further atherosclerosis and may play a role in the increased activation of haemostasis w6, 37x.
(b) Short case series and single case reports have been published on cerebral venous thrombosis (CVT) in adults and children with SLE w56-63; for review, see reference 1x. The presence of APL increases the risk of venous thrombosis in patients with SLE w4, 16x and is suggested to increase the chance of CVT w64, 65x. The association of two such rare disorders as CVT and SLE, even in young adults and children, is a strong argument for the induction of one by the other.
Conclusions. Thrombosis of cerebral arteries and veins is likely to be induced at least in part directly by SLE and complies with the criteria 1 and 4. It is acceptable for inclusion as a mechanism.
1.6: Emboli (MeSH terms: SLE plus intracranial embolism). Cerebral emboli may potentially derive from valvular or endocardial vegetations or from plaques in the carotid artery or other large arteries w32, 41, 66x.
(a) In a prospective study of 69 SLE patients that covered almost 5 yr and in which approximately 60% of the patients had valvular disease, five patients developed ischaemic strokes. They all had cardiovalvular abnormalities w66x.
(b) In case reports, embolization of cardiac origin was demonstrated histologically w67, 68x.
(c) Pathologists agree that some cerebral ischaemic infarcts should be attributed to emboli w41, 42x.
(d) The incidence of transient ischaemic attacks is increased in SLE wfor review, see reference 1x. Some transient ischaemic attacks (TIAs) may be embolic in origin.
Conclusions. Embolism is likely to be the cause of cerebral ischaemia in at least some cases in view of arguments (a) and (b). This contention is supported by arguments (c) and (d). Cerebral embolism complies with Criteria 1 and 4 and is accepted as a mechanism.
I.7: Dissection (MeSH terms: SLE plus the following: CNS disease; cerebral artery diseases; dissection). Dissection of arterial walls may result in arterial occlusion, aneurysmatic widening or haemorrhage. Trauma is probably the most frequent cause of dissection of extracranial arteries; atherosclerosis and vasculitis are risk factors w69x. Figures about the incidence of non-traumatic dissection in the population are not available. Dissection of the aorta was first described in SLE patients, and dissection of extracranial arteries has also been reported in three patients w10, 70x and possibly one other case w71x. It is currently possible to visualize dissection by non-invasive imaging techniques (magnetic resonance angiography or CT angiography), which will facilitate evaluation of its role in cerebral artery occlusion in SLE in the near future.
Conclusions. The possibility should be entertained that dissection contributes significantly to the occurrence of cerebral ischaemic infarcts in SLE. Inclusion of dissection as a mechanism awaits more reports.
I.8: Vasculitis (MeSH terms: SLE plus vasculitis, central nervous system). Although cerebral vasculitis is generally considered to be rare in patients with SLE, there is no denying that it occurs. Post-mortem investigation of brain pathology has shown vasculitis in at least one of 24 cases w41x and changes interpreted as healed vasculitis in the pia-arachnoid in one of 10 cases w43x. Studies of single cases have established cerebral vasculitis by biopsy or post-mortem investigations, in some cases with very convincing illustrations showing the histological findings w72-77x. In other case reports, cerebral vasculitis was established by arteriography w78, 79x. Cerebral vasculitis in SLE may be widespread w78x but in some cases it is restricted to one region w73, 74x or part of one vessel w41x. Localized forms of vasculitis have been reported in patients with aneurysmatic bleeding w77x. Some vasculitides concern small cerebral vessels and others predominantly large arteries w73, 78x.
Conclusions. Cerebral vasculitis complies with Criteria 1 and 4 and is accepted as a mechanism.
1.9: Vessel spasm (MeSH terms: SLE plus the following: disease, Raynaud; migraine). Exposing patients with SLE and Raynaud phenomenon to a cold stressor test provokes defects in cerebral blood diffusion or an increase in such defects in some of them. This does not happen in patients without Raynaud's phenomenon w80x. No clinical syndrome has so far been associated with cerebral vessel spasm.
Conclusions. Spasm of cerebral arteries complies with Criterion 1 but not Criterion 4 and cannot be accepted as a mechanism. (b) This increased incidence has been surmised to be related to several causes: hypertension, hypercholesterolaemia, prolonged corticosteroid medication and changes induced by SLE w34, 35, 81x. Thrombocytopenia may also play a role w34, 35, 81x.
II. Haemorrhage (MeSH terms
(c) In some patients with SLE, subarachnoid haemorrhages remain unexplained, but they are often shown to be due to rupture of a saccular aneurysm or, rarely, a fusiform aneurysm w35, 77, 82x. Interestingly, most reports of cerebral aneurysms in SLE are from Japanese centres. A retrospective investigation revealed that subarachnoid haemorrhage had been diagnosed in 10 of 258 patients. SLE was the only risk factor in five patients. Angiography in eight patients revealed aneurysms in four w82x. According to another Japanese study, 23 SLE patients with cerebral aneurysms had been published by August 1990 w83x. More patients have been described since then w84x. Saccular aneurysms are not congenital but develop w85x. In patients with SLE, aneurysms occur not only in intracranial arteries but also in other arteries w86, 87x.
Conclusions. The incidence of various types of intracranial or spinal haemorrhage is increased in SLE wargument (a)x. The mechanisms underlying the haemorrhages have not been elucidated sufficiently wargument (b)x. The incidence of subarachnoid haemorrhages due to ruptured saccular aneurysms is likely to be increased in Japan wargument (c)x. Table 4 summarizes the types of white matter damage in SLE that are mentioned in the literature. The lesions differ in size, distribution and histology. (a) Clinical. The reversible and relapsing course of some CNS syndromes in patients with SLE w88, 89x resembles the course of relapsing MS, which is primarily a demyelinating disease. Reversibility of clinical signs is, however, not pathognomic for inflammatory demyelination, as demonstrated by TIAs and recovery after stroke.
III. White matter damage
(b) Imaging. Focal changes in the white matter of the brain visualized by MRI are generally held to be due to ischaemic infarcts and oedema, as appears from an analysis of 27 patients w90x, spectroscopic imaging w91x and a recent review w48x.
(c) Histology. Small oval or round areas of myelin vacuolation with some degree of axonal damage, or areas of white matter necrosis with myelin vacuolation at the border of the lesion, have been reported in three patients with SLE, aged 13, 21 and 42 yr w44, 92, 93x. In two of them the areas were clearly localized around veins. The changes were observed throughout the white matter of the brain, basal ganglia and brainstem and the white matter of the spinal cord. Patients presented with subacute encephalopathy, myelopathy or both. These lesions were suggested to be due to acute demyelinating encephalomyelitis (ADEM) complicating SLE w92, 93x. ADEM is rare and affects mostly children. In a patient with incompletely defined SLE, multiple oval lesions with necrosis or myelin vacuolation were observed predominantly in the periphery of the white matter of the spinal cord and were considered to be related to obstruction of small vessels penetrating from the pia-arachnoid into the cord w94x.
Conclusions. Disseminated (perivenous) myelin vacuolation or necrosis of the CNS has been reported in only a few cases and may be an associated CNS autoimmune disease or an SLE-induced mechanism. For the present, it is considered to comply with inclusion Criteria 1 and 4 and is accepted as a mechanism.
III.3: White matter lesions in optic neuropathy and transverse myelitis (MeSH terms: SLE plus the following: optic nerve diseases; optic neuritis; spinal cord diseases; myelitis transverse; neuromyelitis optica). Optic neuropathy or myelopathy each occur in approximately 1% of patients with SLE. Myelopathy is probably somewhat more frequent than optic neuropathy wsee reference 1, section 28, 29: Optic neuropathy and myelopathyx. The two syndromes occur in a substantial minority of patients who are affected consecutively or simultaneously (Devic's syndrome or the 'optic-spinal' form of MS), as shown in a review of 105 cases w95x. Devic's syndrome is considered by some authors to be an autoimmune disease in its own right. The myelopathy of Devic's syndrome extends over two or more vertebrae and is characterized histologically by necrosis and cavitation. The course of Devic's syndrome is monophasic, relapsing or chronic w96-99x.
The MRI of SLE optic neuropathy is not well known. A variable degree of swelling and increased signal intensity on T 2 -weighted images has been described in patients with undefined SLE w100x. The histopathology has not been examined sufficiently w101x.
The most common MRI findings in SLE myelopathy are T 1 and T 2 signal abnormalities and widening of the cord w102x. MRI lesions are longer than those in most cases of MS w103x and similar to those in Devic's syndrome. They may extend over the entire length of the spinal cord w102, 104x. Since 1980, pathological examination of SLE myelopathy has been performed in one case of definite SLE w44x and in two other patients for whom the criteria for the diagnosis SLE criteria were not given w94x. The histological changes in the SLE patient and in one of the patients with undefined SLE comprised oval areas of myelin vacuolization or necrosis, mainly in the periphery of the white matter of the cord. The lesions of the second patient with undefined SLE resembled those seen in a case of SLE described before 1980 w41x. Myelopathy had been present in this latter case for months w41x. At postmortem investigation, 'white matter degeneration' involving myelin and axons was present from the cervical to the sacral segments and over the whole circumference of the cord, most severely in the periphery. Myelin vacuolation was seen at the margins of the lesions, bordering normal white matter w41x.
Spinal cord compression develops in patients with spinal subdural or epidural haematoma (for review, see reference 1, section 17, 18: Subdural and epidural haematomas).
Conclusions. There are still many unanswered questions regarding the nature of SLE-induced optic neuropathy and myelopathy. White matter degeneration in the optic nerve and spinal cord complies with Criteria 1 and 4 and is accepted for inclusion as a mechanism.
III.4: Leucoencephalopathy (MeSH terms: SLE plus leucoencephalopathy). As shown in case reports, leucoencephalopathy may develop in the brain and brainstem of SLE patients within days, weeks or a longer period w55, 105-109x. The lesions may be largely or partly reversible and in such cases are suggested to be due to oedema. In most patients, a definite cause has not been identified. Leucoencephalopathy has, however, been described in a patient with pseudotumour cerebri syndrome w108x.
It is of interest that a reversible type of leucoencephalopathy may develop as a hypertension emergency and in association with drug treatment (cyclosporin, tacrolimus, interferon a, FK 506, erythropoietin) or thrombotic thrombocytopenic purpura and other disorders w110, 111x. These lesions predominate in most cases in posterior parts of the brain, the occipital lobes and the parietal or temporal lobes, spreading from there to other parts. In a large majority of patients they give rise to an encephalopathic syndrome with cerebral loss of vision and other neurological signs wposterior leucoencephalopathy syndrome (PLS)x. PLS has been diagnosed in two patients with lupus nephritis (SLE criteria not given) w110x. Several patients with undefined SLE have been described who had visual complaints and reversible white matter lesions predominating in the occipital poles w112x.
Conclusions. Leucoencephalopathy other than PLS is considered to comply with Criteria 1 and 4 and is admitted for inclusion as a mechanism.
IV: Neuronal dysfunction due to antibodies (Table 5 ) (MeSH terms: SLE plus the following: antibodies; cytokines) Autoantibodies against neuronal membrane receptors may hinder neurotransmission in the CNS and cause neurological signs. An investigation of a specific form of paraneoplastic cerebellar ataxia provided strong arguments for this hypothesis w113x. Antibodies against neuronal nuclear or cytoplasmic antigens are held by some authors not to be neuropathogenetic themselves but to reflect T-lymphocyte activation w114x.
The evidence for a role of antibodies in the pathogenesis of neuronal dysfunction in SLE is at present circumstantial, both from the clinical and from the laboratory point of view. SLE psychosis, defined in DSM IV as a 'disorder due to a general medical condition' w1, 115x, is not related to any known structural changes and recovers without residual abnormalities. Such a course might be explained by antibody-induced reversible neuronal dysfunction. A relationship with neuronal antibodies and cognitive disorder would be conceivable w116x. The neuropathological changes in patients with chorea are in some cases diffuse and not easily explainable by focal vascular abnormalities w117x. An antibody-mediated syndrome would be an alternative. A role for antibodies has also been suggested in the pathogenesis of inappropriate secretion of antidiuretic hormone in SLE w118, 119x.
Though many authors have found antineuronal antibodies in patients with SLE, there is as yet no robust evidence for a causal relationship of a specific antibody with any CNS syndrome. The strongest evidence for a relationship, as far as clinical significance is concerned, is for three ribosomal phosphoproteins (antiribosomal P antibodies) w121x. They are frequent in patients with lupus psychosis and increase during the active phase of this disorder. However, they are not present in all patients with lupus psychosis and are not specific for lupus psychosis or CNS disease w121, 126x.
Cytokines and complement are involved in immunological processes in the CNS but how they interact and contribute to CNS disease and whether they are associated with specific CNS syndromes is not yet clear w127x.
Conclusions. Neuronal dysfunction due to antibodies in SLE-induced CNS disease seems an attractive idea and may explain many CNS syndromes. However, there is still insufficient evidence. It can therefore not yet be accepted as a mechanism for clinical syndromes in SLE.
V: Deficient psychological reactions (MeSH terms: SLE plus the following: coping skill; depression; mood disorder; anxiety disorders) The term 'coping' refers to strategies used by individuals to manage stressful life situations w128, 129x. Physical illnesses may act as a stressful life situation and may precede the onset of depression or elicit anxiety when coping is deficient (insufficient or abnormal) w128, 130, 131x. The liability to develop clinical depression in response to stressful life situations is determined in part by an inherited vulnerability. The results of a study of 46 patients with undefined SLE suggests that the coping strategies used were not disease-specific w132x.
Conclusions. Coping ability and hereditary predisposition are likely to be involved in psychopathological reactions in patients with SLE, as in other chronic diseases. They comply with Criteria 3 and 4 and are acceptable as disease mechanisms in SLE.
Discussion
Current knowledge holds ischaemia to be the main cause of CNS manifestations in SLE. The mechanisms leading to ischaemia are diverse and involve abnormalities of coagulation; thickening of vessel walls due to different causes; the development of focal atherosclerotic plaques in large arteries; and, in some cases, inflammatory processes. In a few patients, CNS syndromes are due to intracranial and intraspinal haemorrhages but the factors that lead to the rupture of vessel walls have not yet been analysed sufficiently. Lesions in the cerebral white matter are in general ischaemic in origin and in a few cases they are due to reversible oedema. The white matter changes in the optic nerves and spinal cord are poorly understood. Antibody-mediated neuronal dysfunction is still under investigation. Deficiency of psychological reactions is likely to play an important role and belongs to another dimension. Table 6 combines the results of the present literature investigation with those of our previous investigation of CNS syndromes in SLE w1x. A modified version of the ACR nomenclature system is shown in the left column. The right column presents possible pathogenetic mechanisms, as reviewed in these two investigations. The advances that have been made in our knowledge of the pathogenetic mechanisms of SLE-induced CNS manifestations have therapeutic consequences. Narrowing of vessels and atherosclerotic plaques develop gradually and are not easily reversible. Interventions for the purpose of primary prevention have been proposed and require evaluation, e.g. prophylactic aspirin and lowering the concentration of serum lipids w133, 134x. Ischaemic infarcts and haemorrhages occur suddenly and in some cases may be open to intervention, such as the thrombolysis of occluded large intracranial arteries w135x and the clipping or coiling of aneurysms w83, 85x. Anticoagulation may be indicated for cerebral sinus thrombosis w136x. In the case of occlusion of arteries, secondary prevention is needed w5, 137x. The efficacy of all these forms of treatment in SLE patients requires investigation and confirmation.
Prevention and new forms of (symptomatic) treatment are not only of interest for TIAs and stroke. Strategies to prevent vascular changes may be relevant to the cognitive functioning of patients. Preparing patients for the uncertainties of their disease may help to prevent psychological reactions. For other CNS syndromes, more insight is needed into their pathogenesis before the same approach is applicable, e.g. the prevention of cerebral oedema in SLE. Though the prevention and treatment of CNS syndromes do not cure SLE, they may improve the patient's well-being and survival. 
